Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Department of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
Am J Pathol. 2019 Jan;189(1):9-21. doi: 10.1016/j.ajpath.2018.10.004.
Pancreatic ductal adenocarcinoma is one of the most aggressive malignant neoplasms with poor outcomes. At the time of diagnosis, the disease is usually at an advanced stage and only a minority is eligible for surgical resection. To improve the prognosis, it is essential to diagnose and treat the disease in an early stage before its progression into an invasive disease. This article reviews clinical features, histopathology, cytopathology, and molecular alterations of pancreatic ductal adenocarcinoma and its precursors. Moreover, we review a recently updated two-tier classification system for precursor lesions, new findings in premalignant cystic neoplasms, and recently updated staging criteria for invasive carcinoma based on the Cancer Staging Manual, eighth edition, from the American Joint Committee on Cancer. Finally, we discuss the potential clinical applications of the rapidly growing molecular and genetic information of pancreatic cancer and its precursors.
胰腺导管腺癌是一种侵袭性最强的恶性肿瘤之一,预后不良。在诊断时,疾病通常处于晚期,只有少数患者适合手术切除。为了改善预后,在疾病进展为侵袭性疾病之前,早期诊断和治疗至关重要。本文回顾了胰腺导管腺癌及其前体的临床特征、组织病理学、细胞学和分子改变。此外,我们还回顾了最近更新的前体病变两阶段分类系统、癌前囊性肿瘤的新发现以及基于美国癌症联合委员会癌症分期手册第八版的侵袭性癌的最新分期标准。最后,我们讨论了胰腺导管腺癌及其前体快速增长的分子和遗传信息的潜在临床应用。